Actively Recruiting
Phase 1 Study Evaluating KK2223 Infusion in Adults with Relapsed or Refractory Peripheral and Cutaneous T-cell Non-Hodgkin Lymphoma
Led by Kyowa Kirin, Inc. · Updated on 2026-09-30
72
Participants Needed
22
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating KK2223 in adults with relapsed or refractory peripheral T cell lymphoma PTCL or cutaneous T cell lymphoma CTCL. This Phase 1, multicenter, open-label, non-randomized study aims to understand the safety, tolerability, pharmacokinetics, and pharmacodynamics of KK2223 in these lymphoma subtypes. The study has two parts a dose-escalation phase and a backfill phase to further assess dosing and safety. Participants will receive KK2223 by intravenous infusion. In Part 1, the study uses a dose-escalation design to find the maximum tolerated dose by gradually increasing dose levels. Part 2 collects additional data at doses found to be tolerable in Part 1, with cohort sizes and dose levels based on earlier results. Enrollment priority may be given to participants in the dose-escalation phase. Throughout the study, participants will undergo regular assessments including safety monitoring for adverse events, blood tests to measure drug levels and immune response, and evaluations of anti-tumor activity. Researchers will monitor treatment effects and drug behavior over approximately 1.5 years. Participants must comply with study procedures and provide tumor tissue samples for evaluation. The study involves periodic visits and monitoring to assess outcomes like safety, drug concentration, and tumor response.
CONDITIONS
Brief Title
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Research Team
K
Kyowa Kirin, Inc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here